Michiel Vermeulen, theme Cancer development and immune defense, is partner in EpiSyStem: Epigenetics and System Biology of Stem cells and Reprogramming - an Innovative Training Network (ITN) funded by the H2020 Marie Sklodowska Curie actions: Paris, France.EpiSyStem is comprised of 8 leading academic partners and 2 professional industrial partners. The Network combines chromatin biology in stem cells, early embryos and reprogramming, including the modelling of human neurological, chromatin-related diseases with bioinformatics, epigenetics / epigenomics, and systems biology at the population and single cell / single embryo level.
This multidisciplinary approach will enable profound training and deep, systems-level understanding of chromatin biology and epigenetic regulation of stem cells, differentiation and reprogramming, with a strong support by industrial partners.
In addition to a competitive training program in a top research institute, successful applicants will enjoy exchange programs, workshops on emerging topics in stem cell epigenetics and bioinformatics, international conferences and meetings, and much more.
There are positions available:
- Institut Curie, France — Genevieve Almouzni
- Hubrecht Institute, Utrecht — Alexander van Oudenaarden
- The Hebrew University of Jerusalem, Israel — Oren Ram; Eran Meshorer
- Radboud University, Nijmegen — Michiel Vermeulen
- Helmholtz Zentrum, Germany — Magdalena Götz; Maria-Elena Torres Padilla
- University of Milan, Italy — Giuseppe Testa
- KadimaStem, Israel
- Diagenode, Belgium
Related news items
Peter-Bram ‘t Hoen appointed as professor of Bioinformatics and head CMBI23 February 2018
The Executive Board has appointed Peter-Bram ‘t Hoen as professor of Bioinformatics with a focus on Personalized Medicine, and head of the Centre for Molecular and Biomolecular Informatics (CMBI) by 1 March 2018.read more
Haloperidol does not prevent delirium or improve survival rates in ICU patients Large-scale study shows commonly used drug has no preventive effect21 February 2018
Prophylactic use of the drug haloperidol does not help to prevent delirium in intensive care patients or improve their chances of survival. Therefore, there is no reason anymore to administer the drug as a preventive measure to reduce the burden of delirium.read more